357 related articles for article (PubMed ID: 15194787)
21. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
[TBL] [Abstract][Full Text] [Related]
22. Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection.
Vasudevachari MB; Zhang YM; Imamichi H; Imamichi T; Falloon J; Salzman NP
Antimicrob Agents Chemother; 1996 Nov; 40(11):2535-41. PubMed ID: 8913459
[TBL] [Abstract][Full Text] [Related]
23. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Metzner KJ; Giulieri SG; Knoepfel SA; Rauch P; Burgisser P; Yerly S; Günthard HF; Cavassini M
Clin Infect Dis; 2009 Jan; 48(2):239-47. PubMed ID: 19086910
[TBL] [Abstract][Full Text] [Related]
24. Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression.
Gantner P; Morand-Joubert L; Sueur C; Raffi F; Fagard C; Lascoux-Combe C; Salmon D; Amiel C; Lambert-Niclot S; Fofana DB; Viard JP; Fafi-Kremer S; Rouzioux C; Avettand-Fenoel V; Ghosn J
J Antimicrob Chemother; 2016 Mar; 71(3):751-61. PubMed ID: 26676973
[TBL] [Abstract][Full Text] [Related]
25. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.
Parisi SG; Boldrin C; Cruciani M; Nicolini G; Cerbaro I; Manfrin V; Dal Bello F; Franchin E; Franzetti M; Rossi MC; Cattelan AM; Romano L; Zazzi M; Andreoni M; Palù G
J Clin Microbiol; 2007 Jun; 45(6):1783-8. PubMed ID: 17442799
[TBL] [Abstract][Full Text] [Related]
26. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
[TBL] [Abstract][Full Text] [Related]
27. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
[TBL] [Abstract][Full Text] [Related]
28. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.
Gonzalez LM; Santos AF; Abecasis AB; Van Laethem K; Soares EA; Deforche K; Tanuri A; Camacho R; Vandamme AM; Soares MA
J Antimicrob Chemother; 2008 Jun; 61(6):1201-4. PubMed ID: 18356151
[TBL] [Abstract][Full Text] [Related]
29. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.
Hance AJ; Lemiale V; Izopet J; Lecossier D; Joly V; Massip P; Mammano F; Descamps D; Brun-Vézinet F; Clavel F
J Virol; 2001 Jul; 75(14):6410-7. PubMed ID: 11413308
[TBL] [Abstract][Full Text] [Related]
30. Phylogenetic analysis of HIV-1 subtypes and drug resistance profile among treatment-naïve people in Kuwait.
Chehadeh W; Albaksami O; Altawalah H; Ahmad S; Madi N; John SE; Abraham PS; Al-Nakib W
J Med Virol; 2015 Sep; 87(9):1521-6. PubMed ID: 25976289
[TBL] [Abstract][Full Text] [Related]
31. Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment.
Kagan RM; Cheung PK; Huard TK; Lewinski MA
Antiviral Res; 2006 Aug; 71(1):42-52. PubMed ID: 16600392
[TBL] [Abstract][Full Text] [Related]
32. Distinctive Drug-resistant Mutation Profiles and Interpretations of HIV-1 Proviral DNA Revealed by Deep Sequencing in Reverse Transcriptase.
Yin QQ; Li ZP; Zhao H; Pan D; Wang Y; Xu WS; Xing H; Feng Y; Jiang SB; Shao YM; Ma LY
Biomed Environ Sci; 2016 Apr; 29(4):239-47. PubMed ID: 27241734
[TBL] [Abstract][Full Text] [Related]
33. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients.
Bon I; Gibellini D; Borderi M; Alessandrini F; Vitone F; Schiavone P; Re MC
J Clin Virol; 2007 Apr; 38(4):313-20. PubMed ID: 17306618
[TBL] [Abstract][Full Text] [Related]
34. HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in Santos, Brazil.
de Sa-Filho DJ; Soares Mda S; Candido V; Gagliani LH; Cavaliere E; Diaz RS; Caseiro MM
AIDS Res Hum Retroviruses; 2008 Mar; 24(3):347-53. PubMed ID: 18327988
[TBL] [Abstract][Full Text] [Related]
35. Performance of the TruGene human immunodeficiency virus type 1 genotyping kit and OpenGene DNA sequencing system on clinical samples diluted to approximately 100 copies per milliliter.
Gale HB; Kan VL; Shinol RC
Clin Vaccine Immunol; 2006 Feb; 13(2):235-8. PubMed ID: 16467331
[TBL] [Abstract][Full Text] [Related]
36. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
37. Comparative performance evaluation of the HIV-1 LiPA protease and reverse transcriptase resistance assay on clinical isolates.
Tsongalis GJ; Gleeson T; Rodina M; Anamani D; Ross J; Joanisse I; Tanimoto L; Ziermann R
J Clin Virol; 2005 Dec; 34(4):268-71. PubMed ID: 16286050
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina.
Vignoles M; Barboni G; Agosti MR; Quarleri J; García MK; Ayala SG; Salomón H
Antivir Ther; 2009; 14(8):1175-81. PubMed ID: 20032547
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naïve patients in Slovenia, 2000-2004.
Babic DZ; Zelnikar M; Seme K; Vandamme AM; Snoeck J; Tomazic J; Vidmar L; Karner P; Poljak M
Virus Res; 2006 Jun; 118(1-2):156-63. PubMed ID: 16417938
[TBL] [Abstract][Full Text] [Related]
40. Short communication: low prevalence of genotypic drug resistance mutations among antiretroviral-naive HIV type 1 patients in Malaysia.
Tee KK; Kamarulzaman A; Ng KP
AIDS Res Hum Retroviruses; 2006 Feb; 22(2):121-4. PubMed ID: 16478392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
